Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Francesco Caso, Luca Cantarini, Filomena Morisco, Antonio Del Puente, Roberta Ramonda, Ugo Fiocco, Ennio Lubrano, Rosario Peluso, Paolo Caso, Mauro Galeazzi, Leonardo Punzi, Raffaele Scarpa & Luisa Costa. (2015) Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opinion on Biological Therapy 15:5, pages 641-650.
Read now
Read now
Chiara Giannitti, Francesca Bellisai, Clodoveo Ferri & Mauro Galeazzi. (2009) Treatment strategies for a patient with rheumatoid arthritis and hepatitis C. Expert Opinion on Pharmacotherapy 10:4, pages 579-587.
Read now
Read now
Bernard Combe. (2008) Update on the use of etanercept across a spectrum of rheumatoid disorders. Biologics: Targets and Therapy 2:2, pages 165-173.
Read now
Read now
Kim A Papp. (2007) The safety of etanercept for the treatment of plaque psoriasis. Therapeutics and Clinical Risk Management 3:2, pages 245-258.
Read now
Read now
Articles from other publishers (27)
Julie J. Hong, Edward K. Hadeler, Megan L. Mosca, Nicholas D. Brownstone, Tina Bhutani & Wilson J. Liao. (2022) TNF-Alpha Inhibitors and Ustekinumab for the Treatment of Psoriasis: Therapeutic Utility in the Era of IL-17 and IL-23 Inhibitors. Journal of Psoriasis and Psoriatic Arthritis 7:2, pages 79-92.
Crossref
Crossref
Orli M Silverberg, Benoit M Cyrenne, David Croitoru, Matthew K Sandre & Kucy Pon. (2022) A case of recalcitrant silicone granuloma treated with adalimumab: A case report. SAGE Open Medical Case Reports 10, pages 2050313X2210934.
Crossref
Crossref
Xining Yang, Wendy M. Toyofuku & Mark D. Scott. (2021) Differential Leukocyte MicroRNA Responses Following Pan T Cell, Allorecognition and Allosecretome-Based Therapeutic Activation. Archivum Immunologiae et Therapiae Experimentalis 69:1.
Crossref
Crossref
Shivani B. Kaushik & Mark G. Lebwohl. (2019) Psoriasis: Which therapy for which patient. Journal of the American Academy of Dermatology 80:1, pages 43-53.
Crossref
Crossref
Claudio Bonifati, Viviana Lora, Dario Graceffa & Lorenzo Nosotti. (2016) Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World Journal of Gastroenterology 22:28, pages 6444.
Crossref
Crossref
Agustin Castiella. (2014) Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. World Journal of Hepatology 6:4, pages 160.
Crossref
Crossref
M. Afshar, A.D. Martinez, R.L. Gallo & T.R. Hata. (2013) Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: A review and analysis of 36 cases. Journal of the European Academy of Dermatology and Venereology 27:6, pages 771-778.
Crossref
Crossref
Laura Padilla-España, Teresa Fernández-Morano, Javier del Boz González, Marta Frieyro Elicegui, Nuria Blázquez Sánchez & Magdalena de Troya Martín. (2012) Etanercept en pacientes con psoriasis e infección crónica por VHC. Piel 27:5, pages 237-240.
Crossref
Crossref
A. M. G. Brunasso, M. Puntoni, A. Gulia & C. Massone. (2011) Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology 50:9, pages 1700-1711.
Crossref
Crossref
S. E. Behnam, R. Hindiyeh, D. J. Fife, E. W. JeffesIIIIII & J. J. Wu. (2010) Etanercept as prophylactic psoriatic therapy before interferon-α and ribavirin treatment for active hepatitis C infection. Clinical and Experimental Dermatology 35:4, pages 397-398.
Crossref
Crossref
Ye H. Oo, Stefan G. Hubscher & David H. Adams. (2010) Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatology International 4:2, pages 475-493.
Crossref
Crossref
Danielle Levine & Bruce E. Strober. (2010) The Treatment of Moderate-to-Severe Psoriasis: Prescreening and Monitoring Psoriatic Patients on Biologics. Seminars in Cutaneous Medicine and Surgery 29:1, pages 28-34.
Crossref
Crossref
Libby RheeAhmed HadiRobert Hasty. (2018) Clinical Application of National Psoriasis Foundation Findings for Management of Psoriasis in Patients with Coexisting Hepatitis C Infection. Psoriasis Forum 15a:2, pages 50-53.
Crossref
Crossref
Amylynne J. Frankel, Abby S. Van Voorhees, Sylvia Hsu, Neil J. Korman, Mark G. Lebwohl, Bruce F. BeboJr.Jr. & Alice B. Gottlieb. (2009) Treatment of psoriasis in patients with hepatitis C: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology 61:6, pages 1044-1055.
Crossref
Crossref
Bruce Strober, Emily Berger, Jennifer Cather, David Cohen, Jeffrey J. Crowley, Kenneth B. Gordon, Alice Gottlieb, Elizabeth J. Horn, Arthur F. Kavanaugh, Neal J. Korman, Gerald G. Krueger, Craig L. Leonardi, Alan Menter, Sergio Schwartzman, Jeffrey M. Sobell & Melodie Young. (2009) A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach. Journal of the American Academy of Dermatology 61:1, pages S1-S46.
Crossref
Crossref
Alfredo Papa, Giammarco Mocci, Michele Bonizzi, Carla Felice, Gianluca Andrisani, Italo De Vitis, Luisa Guidi & Antonio Gasbarrini. (2009) Use of Infliximab in Particular Clinical Settings: Management Based on Current Evidence. The American Journal of Gastroenterology 104:6, pages 1575-1586.
Crossref
Crossref
Xinaida T. Lima, Elizabeth M. Seidler, Hermênio C. Lima & Alexandra B. Kimball. (2009) Long-term safety of biologics in dermatology. Dermatologic Therapy 22:1, pages 2-21.
Crossref
Crossref
AJ Alcaide, MV Barrera, S Habicheyn, N López, MV Mendiola & E Herrera. (2008) Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection. Journal of the European Academy of Dermatology and Venereology 22:12, pages 1514-1516.
Crossref
Crossref
Emily M. Berger & Alice B. Gottlieb. 2008. Clinical and Basic Immunodermatology. Clinical and Basic Immunodermatology
481
526
.
S. Aslanidis, T. Vassiliadis, A. Pyrpasopoulou, I. Douloumpakas & C. Zamboulis. (2006) Inhibition of TNFα does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clinical Rheumatology 26:2, pages 261-264.
Crossref
Crossref
Maria R. Robinson & Neil J. Korman. (2018) Psoriasis and Co-Morbidities: Approach to Treatment with Biologics. Psoriasis Forum 12a:2, pages 10-15.
Crossref
Crossref
Aja M. Sanzone & Rodolfo E. Bégué. (2006) Hepatitis C and Arthritis: An Update. Infectious Disease Clinics of North America 20:4, pages 877-889.
Crossref
Crossref
Sheetal B. Desai & Daniel E. Furst. (2006) Problems encountered during anti-tumour necrosis factor therapy. Best Practice & Research Clinical Rheumatology 20:4, pages 757-790.
Crossref
Crossref
Shannon B. Routhouska & Neil J. Korman. (2018) Initiating and Monitoring Patients on Biologic Therapy for Psoriasis beyond the FDA: Our more Cautious Approach. Psoriasis Forum 12a:1, pages 12-15.
Crossref
Crossref
Bruce E. Strober. (2005) The treatment of psoriasis with etanercept. Seminars in Cutaneous Medicine and Surgery 24:1, pages 28-36.
Crossref
Crossref
J. Ledingham & C. Deighton. (2005) Update on the British Society for Rheumatology guidelines for prescribing TNF blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 44:2, pages 157-163.
Crossref
Crossref
Melissa Amy Magliocco & Alice Bendix Gottlieb. (2004) Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: Report of 3 cases. Journal of the American Academy of Dermatology 51:4, pages 580-584.
Crossref
Crossref